Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
23 juil. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the submission of an sNDA in scalp and body psoriasis.
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
03 nov. 2023 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended September 30, 2023, and provided a business update.
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
13 oct. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for treatment of adults/adolescents with scalp/body psoriasis.
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
10 août 2023 08h16 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit tiered royalties WESTLAKE VILLAGE,...
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
08 août 2023 16h02 HE
|
Arcutis Biotherapeutics, Inc.
Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of...
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
18 avr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
FDA has set a target action date of December 16, 2023NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foamIf approved, roflumilast foam...
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
09 mars 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis...
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
28 févr. 2023 16h02 HE
|
Arcutis Biotherapeutics, Inc.
Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growthSecured expanded commercial...
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
21 févr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic...
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
08 nov. 2022 16h02 HE
|
Arcutis Biotherapeutics, Inc.
Launched ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in adolescents and adults in mid-August, achieving net revenues of $0.7 million for the third quarterZORYVE now covered...